



PRESS RELEASE

COREMEDIC ANNOUNCES SUCCESSFUL TRANSCATHETER APPLICATION OF MITRAL VALVE CHORDAL REPAIR DEVICE CHORDART™

Radolfzell, November 8, 2023. CoreMedic GmbH announces the world's first successful transcatheter application of the ChordArt™ technology for mitral valve repair. The patient, who suffered from severe degenerative mitral regurgitation due to mitral leaflet flail, was successfully treated as part of CoreMedic's First-in-Human trial for percutaneous mitral chordae tendineae replacement with the ChordArt™ TMVr-System. This has the potential to fundamentally change the treatment of Primary Mitral Regurgitation, a severe disease that effects millions of people around the world.

Josef Bogenschütz, CEO of CoreMedic GmbH stated: "We are thrilled to achieve this historic milestone with our revolutionary ChordArt™ TMVr-System, a novel approach for percutaneous mitral valve repair. Thank you to all who played a crucial role in making this success true. This achievement is a testament to the dedication and hard work of our exceptional team, and we are deeply appreciative of their contributions. Our cutting-edge solution enables us to position ourselves as leaders in the field of catheter based mitral valve repair. We are committed to redefining the gold standard, thereby setting new benchmarks for excellence in the future".

Thomas Bauer, CTO and co-founder of CoreMedic GmbH, stated: "We are very happy for the patient and are delighted about the technical success as well. Results from the 5-year follow-up of our initial surgical study with the ChordArt™-System have been exceptionally promising. Now we have demonstrated the ability to percutaneously deliver this implant less invasively, via the transfemoral, transseptal route – an outstanding achievement, which the whole cross-functional team is extremely proud of."



The ChordArt™ device is being developed as catheter-based first line treatment option for Primary Mitral Regurgitation (PMR). PMR is one of the most common heart valve diseases and a growing medical burden, particularly in aging societies, affecting more than 25 million patients worldwide. The device is designed to enable safe and effective repair of the mitral valve by replacing damaged mitral valve chords with a physiological approach respecting the natural anatomy. Due to its minimal footprint, the implant keeps the door open for possible future therapy needs.

Prof. Alberto Weber, Founder and Chief Medical Officer of CoreMedic GmbH, announced: "Percutaneous, transseptal mitral valve repair of flail leaflets is now a reality. A safe and reproducible solution that invites an end to watchful waiting in patients with severe degenerative mitral regurgitation. My special thanks to the professionals who made this patient happy: Prof. Maurizio Taramasso, Prof. Michel Zuber and Leonora Zuberi from our Swiss team as well as Prof. Kęstutis Ručinskas, Dr. Diana Zakarkaitė, Dr. Andrej Podkopajev, Dr. Vilnius Janušauskas and Prof. Giedrius Davidavičius at the University Hospital in Vilnius, Santaros Klinikos, Lithuania."

About Mitral Regurgitation

Mitral valve regurgitation (MR) is a condition in which the mitral valve leaflets fail to close properly, allowing significant backflow of blood from the left ventricle into the left atrium during systole. Valve disease prevalence rises dramatically with age, reaching critical dimensions in the elderly societies that are known to be aging.

MR is the most common valve pathology in Europe and US with a prevalence of 2% across the population and >10% in persons aged 75+ years. If untreated, MR can cause shortness of breath, decreased cardiac output, intolerance to physical exercise, congestive heart failure and death.

The standard-of-care in surgically treating degenerative MR (PMR) involves replacement ruptured or elongated valve chords with artificial implants to restore the function of the valve. Implanting the standard artificial chordae requires complex and long procedural steps inherent to open heart surgery. This complexity is associated with risks including failure of the valve repair or the need to repeat the operation, the use of a cardiac bypass machine and stopping temporarily the heart. The ChordArt™ TMVr-System enables a catheter-based therapy approach that avoids the need for open heart surgery in PMR patients suffering from ruptured or elongated chordae tendineae.



About CoreMedic:

CoreMedic GmbH is an innovative cardiology company, located in Radolfzell, Germany. As a spin-off of the Heart Center of University of Bern, Switzerland, CoreMedic was initiated in 2012 to develop the breakthrough treatment concept for mitral valve regurgitation ChordArt™. The company is backed by a group of experienced and committed private investors with backgrounds in heart medicine and cardiovascular devices and institutional healthcare investor SHS (www.shs-capital.eu).

About ChordArt™:

The ChordArt™ Transcatheter Mitral Valve repair (TMVr) - System is designed to improve chorda repair procedures across all crucial parameters. These include the reduction of patient trauma, duration of procedure and complexity as well as operator dependency and time of recovery for the patient. ChordArt™ is a catheter designed to deliver implants percutaneously allowing interventions in high-risk as well as asymptomatic patients, which are not eligible for treatment with the current "Gold Standard" of chordal replacement via open-heart surgery.

For further information, please visit www.coremedic.de or feel free to contact us via info@coremedic.de or under +49 171 4269395.

PR Contact:

Thomas Bauer
Managing Director
CoreMedic GmbH
Fritz-Reichle-Ring 2
78315 Radolfzell
GERMANY